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Background: No consensus has been reached regarding the optimal surgical treatment for focal chondral defects of the talus.
Purpose: A Bayesian network meta-analysis was conducted to compare the clinical scores and complications of mosaicplasty,
osteochondral auto- and allograft transplant, microfracture, matrix-assisted autologous chondrocyte transplant, and autologous
matrix-induced chondrogenesis (AMIC) for chondral defects of the talus at midterm follow-up.
Study Design: Bayesian network meta-analysis; Level of evidence, 4.
Methods: This Bayesian network meta-analysis followed the PRISMA (Preferred Reporting Items for Systematic Reviews and
Meta-Analyses) extension statement for reporting of systematic reviews incorporating network meta-analyses of health care in-
terventions. PubMed, Embase, Google Scholar, and Scopus databases were accessed in February 2021. All clinical trials com-
paring 2 or more surgical interventions for the management of chondral defects of the talus were accessed. The outcomes of
interest were visual analog scale (VAS) score, American Orthopaedic Foot and Ankle Society (AOFAS) score, rate of failure,
and rate of revision surgery. The network meta-analysis were performed through the routine for Bayesian hierarchical random-
effects model analysis. The log odds ratio (LOR) effect measure was used for dichotomous variables, and the standardized
mean difference (SMD) was used for continuous variables.
Results: Data from 13 articles (521 procedures) were retrieved. The median length of the follow-up was 47.8 months (range, 31.7-
66.8 months). Analysis of variance revealed no difference between the treatment groups at baseline in terms of age, sex, body
mass index, AOFAS score, VAS score, and mean number of defects. AMIC demonstrated the greatest AOFAS score (SMD, 11.27)
and lowest VAS score (SMD, –2.26) as well as the lowest rates of failure (LOR, 0.94) and revision (LOR, 0.94). The test for overall
inconsistency was not significant.
Conclusion: At approximately 4 years of follow-up, the AMIC procedure for management of focal chondral defects of the talus
produced the best outcome.
Keywords: talus; chondral defect; AMIC; OAT
Focal chondral defects of the talus are common.35 Given
the limited intrinsic regeneration capability of cartilage,
surgical intervention can be necessary.15,30 If left
untreated, patients can experience increasing pain,
reduced quality of life, reduced sporting activity, and early
osteoarthritis.29 Traditionally, microfracture has been con-
sidered the first-line intervention for focal chondral defects
of the talus.13 Several osteochondral transplant procedures
have been proposed. With osteochondral autograft or allo-
graft transplant (OAT), an osteochondral graft is harvested
from a nonweightbearing zone of the knee and
transplanted to fill the chondral defect of the talus.1,16
With mosaicplasty, several osteochondral grafts or plugs
are harvested from a nonweightbearing zone of the knee
to produce a mosaic-like structure.37 In matrix-assisted
autologous chondrocyte transplantion (MACT), chondro-
cytes harvested from a nonweightbearing area of the
knee are cultivated, expanded, and implanted into a mem-
brane.27,28 In a second surgical session, the chondrocyte-
loaded membrane is transplanted into the defect with cus-
tom-made instruments in a full arthroscopic fashion.34
Recently, autologous matrix-induced chondrogenesis
(AMIC) has been proposed for the management of chondral
defects of the talus.3,5 AMIC exploits the regenerative
potential of bone marrow–derived cells.9,17
Despite all these options, it is unclear which is the opti-
mal surgical treatment for focal chondral defects of the
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talus, and no consensus has been reached. To the best of
our knowledge, no network meta-analysis has been con-
ducted previously to evaluate the treatments for talar
chondral defects. Therefore, a Bayesian network meta-
analysis was conducted to compare these strategies for
the surgical management of chondral defects of the talus
at midterm follow-up. The present study compared the effi-




This Bayesian network meta-analysis followed the
PRISMA (Preferred Reporting Items for Systematic
Reviews and Meta-Analyses) extension statement for
reporting of systematic reviews incorporating network
meta-analyses of health care interventions.25 Before the
literature search was conducted, the PICOT framework
was established as follows:
 P (Problem): focal chondral defect of the talus
 I (Intervention): surgical management
 C (Comparison): AMIC, OAT, microfracture, mosaic-
plasty, MACT
 O (Outcomes): clinical scores and complications
 T (Timing): 18 months of follow-up
Data Source
Two authors (F.M., A.B.) conducted the literature search
independently. PubMed, Embase, Google Scholar, and Sco-
pus databases were accessed in February 2021. The follow-
ing keywords were used in combination: ankle, talus,
cartilage, damage, chondral, articular, injury, chondrop-
athy, focal, defect, pain, membrane, autologous matrix-
induced chondrogenesis, matrix-assisted autologous chon-
drocyte transplantation, MACT, AMIC, OAT, cylinder,
osteochondral, transplantation, outcomes, microfractures,
failures, surgery, management, allograft, autograft, fail-
ure, revision. The same authors independently screened
the resulting articles. The full-text versions of the articles
of interest were accessed, and a cross-reference of the bib-
liographies was conducted. Divergences were solved by
a third author (N.M.).
Eligibility Criteria
All clinical trials that compared 2 or more surgical interven-
tions for the management of talar chondral defects were
accessed. Given the authors’ language abilities, articles in
English, German, Italian, French, and Spanish were eligible.
Only studies of level I to IV of evidence, according to the
Oxford Centre of Evidence-Based Medicine,24 were consid-
ered. Other eligibility criteria were studies that focused on
AMIC, OAT, microfracture, MACT, and mosaicplasty;
involved patients with a focal lesion of the talus; reported
data on a minimum of 10 patients; clearly stated the type
of intervention; had a minimum of 18 months of follow-up;
and reported quantitative data under the outcomes of inter-
est. Not eligible were studies involving patients with end-
stage joint osteoarthritis or patients with kissing lesions; ani-
mal, computational, or biomechanical studies; and studies
augmenting the procedures with less committed cells (eg,
mesenchymal stem cells).
Data Extraction
Two authors (F.M., A.B.) separately performed data
extraction. Study details such as author, year, journal,
study design, and length of follow-up were retrieved.
Data regarding patient characteristics at baseline were
collected: number of procedures, defect size, patients’
mean age and body mass index (BMI), and patients’ sex.
Also retrieved were visual analog scale (VAS) and Ameri-
can Orthopaedic Foot and Ankle Society (AOFAS)41 scores
and the rates of failure and revision surgeries. Failure was
defined as recurrence of pain and/or catching symptoms,
graft hypertrophy, and/or partially or completely displaced
delamination seen on magnetic resonance imaging (MRI)
or arthroscopic examination.23,31,32
Methodological Quality Assessment
Two independent authors assessed methodological quality
(F.M., A.B.) using the risk of bias graph tool of the Review
Manager software (The Nordic Cochrane Collaboration).
The following factors pertaining to risk of bias were evalu-
ated: selection, detection, reporting, attrition, and other
source of bias.
Statistical Analysis
The statistical analysis was performed by the main author
(F.M.), using STATA software/MP (Stata Corporation). To
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assess baseline data, the Shapiro-Wilk test was performed
to investigate data distribution. For parametric data, mean
and standard deviation were evaluated. Baseline compara-
bility of parametric data was assessed using analysis of
variance (ANOVA), with P . .1 considered satisfactory.
For nonparametric data, median and interquartile range
were evaluated. The baseline comparability of nonpara-
metric data was assessed by the Kruskal-Wallis test,
with P . .1 considered satisfactory. Network meta-analy-
sis were performed through the STATA routine for Bayes-
ian hierarchical random-effects model analysis. The
inverse variance method was used for all of the compari-
sons. The log odds ratio (LOR) effect measure was used
for dichotomous variables, whereas the standardized
mean difference (SMD) was used for continuous variables.
Overall inconsistency was evaluated through the equation
for global linearity via the Wald test. If the P value was
..1, the null hypothesis could not be rejected, and the con-
sistency assumption was accepted at the overall level of
each treatment. All variables were compared in the net-
work analyses against a fictitious group control: no event
for binary comparisons and the maximal value of a score
for continuous endpoints. For each outcome of interest,
we constructed edge, interval, and funnel plots. Edge plots
demonstrate the amount of a direct comparison and its
weight in the overall network analysis. Interval plots
rank the estimate effect related to each treatment result-
ing from the network comparisons. For the interval plots,
both confidence intervals and percentile intervals were
set at 95%. Funnel plots investigate the risk of bias of
the outcome of interest considered; greater asymmetry in
the plot was associated with a greater risk of bias.
RESULTS
Search Result
The literature search resulted in 905 articles; of them, 274
were duplicates. A further 610 articles were not compatible
with the eligibility criteria: noncomparative study (n =
309), not focused on talus (n = 192), short follow-up (n =
8), included kissing lesion (n = 7), not focused on focal
defect (n = 12), combined with stem cells (n = 10), language
limitations (n = 2), reported on other surgical interventions
(n = 51), and other (n = 19). A further 8 studies did not
report quantitative data under the outcomes of interest.
This left 13 articles for inclusion in the present study.
The literature search results are shown in Figure 1.
Methodological Quality Assessment
Given the large number of retrospective comparative stud-
ies (10/13), the risk of selection bias was high. Assessor
blinding was performed in 10 of the 13 studies, resulting
in a low risk of detection bias. The risks of attrition bias
and reporting bias were moderate to low, as were the risks
of other bias. The overall score for risk of bias was low,
attesting that this study had moderate to good methodolog-
ical quality. The risk of bias graph is shown in Figure 2.
Patient Characteristics
Data on 521 procedures were retrieved. The median length
of follow-up was 47.8 months (range, 31.7-66.8 months). Of
all patients, 42.4% (221/521) were women. The mean 6 SD
age of the patients was 35.0 6 8.0 years, and the mean BMI
was 25.1 6 1.1. The mean defect size was 2.0 6 1.6 cm2. At
baseline, the mean VAS score was 7.4. 6 0.9 and the mean
AOFAS score was 47.0 6 8.2. The ANOVA revealed no dif-
ference between the treatment groups at baseline in terms
Figure 1. Flowchart of the literature search using the
PRISMA (Preferred Reporting Items for Systematic Reviews
and Meta-Analyses) guidelines.
Figure 2. Methodological quality assessment.
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of mean age and BMI, patient sex, defect size, and VAS and
AOFAS scores (P . .1). Details of the studies are shown in
Table 1.
Outcomes of Interest
AMIC produced the highest AOFAS scores (SMD, 11.27;
95% CI, –2.12 to 24.67) and lowest VAS scores (SMD,
–2.26; 95% CI, –7.24 to 2.72). The test for overall inconsis-
tency was not significant (P = .6). Edge, funnel, and inter-
val plots of the scores are shown in Figure 3.
Complications
AMIC demonstrated the lowest rates of failure (LOR, 0.94;
95% CI, –1.86 to 3.74) and revision (LOR, 0.94; 95% CI, –
1.86 to 3.74). OAT evidenced the highest rates of failure
(LOR, 3.48; 95% CI, 1.87 to 5.08) and revision (LOR,
4.60; 95% CI, 2.68 to 6.51). The test for overall inconsis-
tency was not significant (P = .8). Edge, funnel, and inter-
val plots of complications are shown in Figure 4.
DISCUSSION
The present Bayesian network meta-analysis demon-
strated that AMIC for the management of focal osteochon-
dral lesions of the talus performed better overall at
approximately 4 years of follow-up. Patients undergoing
OAT with allograft experienced the highest rate of compli-
cations, whereas microfracture resulted in the lowest val-
ues of patient-reported outcome measures.
To the best of our knowledge, this is the first Bayesian
network meta-analysis to rank the treatments for talar
chondral defects. AMIC exploits the potential of autologous
bone marrow–derived mesenchymal stem cells, avoiding
the harvesting of nonweightbearing cartilage, cell culture,
and expansion. Moreover, being a single-stage procedure,
it may present an attractive option for both patients and
surgeons. The available scientific literature lacks head-
to-head studies that compare AMIC with other surgical
techniques for the management of knee chondral defects.
Becher et al7 compared AMIC versus microfracture in
a cohort of 32 patients (16 patients each group) with a min-
imum follow-up of 5 years, evidencing no differences in out-
come. D’Ambrosi et al,9 using AMIC in a cohort of 17 young
TABLE 1
Details of the Included Studiesa









Ahmad2 (2016) Foot Ankle Int Randomized OAT: allograft 40.5 16 37.5 39.7
OAT: autograft 35.2 20 45.0 41.3
Apprich4 (2012) Osteoarthritis Cartilage Retrospective MACT 48.0 10 60.0 31.0
MFX 59.6 10 40.0 32.4
Becher7 (2019) Knee Surg Sports
Traumatol Arthrosc
Retrospective MFX 67.2 16 56.3 33.3
AMIC 68.4 16 56.3 32.4
D’Ambrosi9 (2017) Arthroscopy Retrospective AMIC 27.0 17 52.9 25.0
AMIC 14 26.0 47.0
Domayer12 (2012) Osteoarthritis Cartilage Retrospective MFX 113.8 10 55.6 30.8
MACT 65.4 10 77.8 25.4
Gobbi18 (2006) Arthroscopy Prospective MFX 53.0 10 40.0 24.0
Control group 11 45.5 32.0
OAT: autograft 12 33.3 27.8
Gül20 (2016) J Foot Ankle Surg Retrospective OAT: autograft 30.5 15 33.3 32.6
OAT: autograft 28.9 13 8.3 36.7
Guney21 (2016) Knee Surg Sports
Traumatol Arthrosc
Prospective MFX 47.3 19 37.4 47.4
Control group 40.4 22 43.9 50.0
Mosaicplasty 30.1 13 37.6 15.4
Haleem22 (2014) Am J Sports Med Retrospective OAT: autograft 93.0 14 50.0 42.8
OAT: autograft 85.3 28 39.3 44.1
Park33 (2018) Am J Sports Med Retrospective OAT: autograft 71.4 18 41.6
OAT: autograft 28
Shimozono38 (2018) Am J Sports Med Retrospective OAT: autograft 52.0 63 42.9 36.0
OAT: autograft 45.0 31 32.3 34.0
Shimozono38 (2018) Bone Joint Surg Am Retrospective OAT: autograft 26.3 25 64.0 38.4
OAT: allograft 22.3 16 37.5 43.6
Yoon44 (2014) Am J Sports Med Retrospective OAT: autograft 45.0 22 31.8 37.1
MFX 50.0 22 18.2 41.6
aAMIC, autologous matrix-induced chondrogenesis; MACT, matrix-assisted autologous chondrocyte transplant; MFX, microfracture;
OAT, osteochondral autograft or allograft transplant.
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versus 14 old patients, concluded that AMIC was a reliable
procedure regardless of patient age and that clinical out-
come may depend on the preoperative conditions of the
ankle. Walther et al42 performed a systematic review and
meta-analysis including 12 studies (492 procedures).
Although their analysis was affected by a high grade of
heterogeneity, they evidenced a statistically significant
improvement of AOFAS, VAS, and Foot Function Index
scores.8 Given the lack of quantitative data, return to
sports was not included in the network comparisons.
Figure 3. Edge, funnel, and interval plots of scores: American Orthopaedic Foot and Ankle Society and visual analog scale.
AMIC, autologous matrix-induced chondrogenesis; MACT, matrix-assisted autologous chondrocyte transplantation; MFX, micro-
fracture; OAT, osteochondral autograft or allograft transplant; PrI, percentile interval.
Figure 4. Edge, funnel, and interval plots of complications: failure and revision. AMIC, autologous matrix-induced chondrogen-
esis; MFX, microfracture; OAT, osteochondral autograft or allograft transplant; PrI, percentile interval.
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D’Ambrosi et al10 retrospectively analyzed return to sports
in a cohort of patients after AMIC: 80.8% (21/26) of
patients returned to sports within 42.6 months.
Our network comparison indicated that autografts for
osteochondral transplant performed better than allografts.
These observations agree with previous head-to-head stud-
ies that compared the 2 grafts. Ahmad and Jones2 compared
autograft versus allograft in a cohort of 40 patients in a ran-
domized clinical trial. The results were comparable, but
allografts had lower healing rates. Shimozono et al38 found
better clinical and MRI outcomes and a lower rate of failure
in the allograft group in a cohort of 25 patients. Allografts
have been introduced to avoid harvesting morbidity, with
initially promising results.14 However, allografts may dete-
riorate over time.43 MRI studies show that allografts are not
properly incorporated in some patients, and cartilage fis-
sures or cysts close to the host-graft interface are more fre-
quent when allografts are used versus autografts.14,19
Further studies are required to clearly establish the pros
and cons of both type of osteochondral transplant.
The present network meta-analysis is not without limita-
tions. The most important limitations are the retrospective
nature of the design and the overall poor quality of many
of the included studies. The analyses were performed
regardless of the surgical approach (arthroscopy, mini-
arthrotomy, arthrotomy), the nature of the membrane (col-
lagen or hyaluronic acid), the fixation methods (glue, fibrin,
both, none), and the location of the lesion on the articular
surface. Given the lack of comparative studies, autologous
chondrocyte implant and particulated juvenile articular car-
tilage techniques were not included for analysis. Because of
the limited available data, articles were considered regard-
less of the cause of the chondral defect, and further differen-
tiation between primary and revision settings was not
possible. The lack of quantitative data prevented compari-
son of the time to return to sports. Most authors reported
data of interventions combined with other surgical proce-
dures, such as osteotomy or ligament repair. Given the
lack of data concerning complications, it was not possible
to separately analyze the causes of failure. The heteroge-
neous procedures and the limited available data precluded
evaluation of the use of mesenchymal stem cells.
Regenerative medicine is rapidly evolving through the
use of mesenchymal stem cells and via better understanding
of the cellular and molecular basis of hyaline cartilage heal-
ing. Future studies should overcome the current obstacles to
clinical translation—namely, cell source, cell isolation, and
expansion and differentiation methods. In the past few
years, several protocols for cell processing have been devel-
oped, but no consensus has been reached. Deeper under-
standing of the interactions between mesenchymal stem
cells and the microenvironment, related signaling patterns,
and influence on the regenerative cascade is required to
develop appropriate therapeutic protocols. Given these con-
troversies, studies using mesenchymal stem cells were not
included. The AOFAS score is one of the most commonly
used scores to assess foot and ankle ailments.36,40 However,
whether the AOFAS score is a valid and reliable measure
for assessment is controversial.6,11,26,39 In view of these lim-
itations, results must be interpreted with caution.
CONCLUSION
At approximately 4 years of follow-up, AMIC displayed the
most reliable results for the management of focal chondral





1. Adams SB, Dekker TJ, Schiff AP, et al. Prospective evaluation of
structural allograft transplantation for osteochondral lesions of the
talar shoulder. Foot Ankle Int. 2018;39(1):28-34.
2. Ahmad J, Jones K. Comparison of osteochondral autografts and
allografts for treatment of recurrent or large talar osteochondral
lesions. Foot Ankle Int. 2016;37(1):40-50.
3. Albano D, Martinelli N, Bianchi A, et al. Clinical and imaging outcome
of osteochondral lesions of the talus treated using autologous matrix-
induced chondrogenesis technique with a biomimetic scaffold. BMC
Musculoskelet Disord. 2017;18(1):306.
4. Apprich S, Trattnig S, Welsch GH, et al. Assessment of articular car-
tilage repair tissue after matrix-associated autologous chondrocyte
transplantation or the microfracture technique in the ankle joint using
diffusion-weighted imaging at 3 Tesla. Osteoarthritis Cartilage.
2012;20(7):703-711.
5. Baumfeld T, Baumfeld D, Prado M, Nery C. All-arthroscopic AMIC
(AT-AMIC) for the treatment of talar osteochondral defects: a short
follow-up case series. Foot (Edinb). 2018;37:23-27.
6. Baumhauer JF, Nawoczenski DA, DiGiovanni BF, Wilding GE. Reli-
ability and validity of the American Orthopaedic Foot and Ankle Soci-
ety Clinical Rating Scale: a pilot study for the hallux and lesser toes.
Foot Ankle Int. 2006;27(12):1014-1019.
7. Becher C, Malahias MA, Ali MM, Maffulli N, Thermann H. Arthro-
scopic microfracture vs. arthroscopic autologous matrix-induced
chondrogenesis for the treatment of articular cartilage defects of
the talus. Knee Surg Sports Traumatol Arthrosc. 2019;27(9):2731-
2736.
8. Budiman-Mak E, Conrad KJ, Mazza J, Stuck RM. A review of the foot
function index and the foot function index–revised. J Foot Ankle Res.
2013;6(1):5.
9. D’Ambrosi R, Maccario C, Serra N, Liuni F, Usuelli FG. Osteochon-
dral lesions of the talus and autologous matrix-induced chondrogen-
esis: is age a negative predictor outcome? Arthroscopy. 2017;33(2):
428-435.
10. D’Ambrosi R, Villafane JH, Indino C, et al. Return to sport after arthro-
scopic autologous matrix-induced chondrogenesis for patients with
osteochondral lesion of the talus. Clin J Sport Med. 2019;29(6):
470-475.
11. De Boer AS, Meuffels DE, Van der Vlies CH, et al. Validation of the
American Orthopaedic Foot and Ankle Society Ankle-Hindfoot Scale
Dutch language version in patients with hindfoot fractures. BMJ
Open. 2017;7(11):e018314.
12. Domayer SE, Apprich S, Stelzeneder D, et al. Cartilage repair of the
ankle: first results of T2 mapping at 7.0 T after microfracture and
matrix associated autologous cartilage transplantation. Osteoarthritis
Cartilage. 2012;20(8):829-836.
13. Duramaz A, Baca E. Microfracture provides better clinical results
than debridement in the treatment of acute talar osteochondral
lesions using arthroscopic assisted fixation of acute ankle fractures.
Knee Surg Sports Traumatol Arthrosc. 2018;26(10):3089-3095.
14. El-Rashidy H, Villacis D, Omar I, Kelikian AS. Fresh osteochondral
allograft for the treatment of cartilage defects of the talus: a retro-
spective review. J Bone Joint Surg Am. 2011;93(17):1634-1640.
6 Migliorini et al The American Journal of Sports Medicine
15. Filardo G, Perdisa F, Roffi A, Marcacci M, Kon E. Stem cells in artic-
ular cartilage regeneration. J Orthop Surg Res. 2016;11:42.
16. Fraser EJ, Harris MC, Prado MP, Kennedy JG. Autologous osteo-
chondral transplantation for osteochondral lesions of the talus in an
athletic population. Knee Surg Sports Traumatol Arthrosc.
2016;24(4):1272-1279.
17. Galla M, Duensing I, Kahn TL, Barg A. Open reconstruction with
autologous spongiosa grafts and matrix-induced chondrogenesis
for osteochondral lesions of the talus can be performed without
medial malleolar osteotomy. Knee Surg Sports Traumatol Arthrosc.
2019;27(9):2789-2795.
18. Gobbi A, Francisco RA, Lubowitz JH, Allegra F, Canata G. Osteo-
chondral lesions of the talus: randomized controlled trial comparing
chondroplasty, microfracture, and osteochondral autograft trans-
plantation. Arthroscopy. 2006;22(10):1085-1092.
19. Gomoll AH, Madry H, Knutsen G, et al. The subchondral bone in
articular cartilage repair: current problems in the surgical manage-
ment. Knee Surg Sports Traumatol Arthrosc. 2010;18(4):434-447.
20. Gül M, Cetinkaya E, Aykut US, et al. Effect of the presence of sub-
chondral cysts on treatment results of autologous osteochondral
graft transfer in osteochondral lesions of the talus. J Foot Ankle
Surg. 2016;55(5):1003-1006.
21. Guney A, Yurdakul E, Karaman I, et al. Medium-term outcomes of
mosaicplasty versus arthroscopic microfracture with or without
platelet-rich plasma in the treatment of osteochondral lesions of
the talus. Knee Surg Sports Traumatol Arthrosc. 2016;24(4):1293-
1298.
22. Haleem AM, Ross KA, Smyth NA, et al. Double-plug autologous
osteochondral transplantation shows equal functional outcomes
compared with single-plug procedures in lesions of the talar dome:
a minimum 5-year clinical follow-up. Am J Sports Med.
2014;42(8):1888-1895.
23. Hoburg A, Loer I, Korsmeier K, et al. Matrix-associated autologous
chondrocyte implantation is an effective treatment at midterm
follow-up in adolescents and young adults. Orthop J Sports Med.
2019;7(4):2325967119841077.
24. Howick J, Chalmers I, Glasziou P, et al. The 2011 Oxford CEBM
Levels of Evidence. Oxford Centre for Evidence-Based Medicine.
Accessed September 2020. https://wwwcebmnet/indexaspx?o=5653
25. Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension state-
ment for reporting of systematic reviews incorporating network meta-
analyses of health care interventions: checklist and explanations.
Ann Intern Med. 2015;162(11):777-784.
26. Ibrahim T, Beiri A, Azzabi M, et al. Reliability and validity of the sub-
jective component of the American Orthopaedic Foot and Ankle
Society clinical rating scales. J Foot Ankle Surg. 2007;46(2):65-74.
27. Kon E, Filardo G, Condello V, et al. Second-generation autologous
chondrocyte implantation: results in patients older than 40 years.
Am J Sports Med. 2011;39(8):1668-1675.
28. Kon E, Gobbi A, Filardo G, et al. Arthroscopic second-generation
autologous chondrocyte implantation compared with microfracture
for chondral lesions of the knee: prospective nonrandomized study
at 5 years. Am J Sports Med. 2009;37(1):33-41.
29. Litwic A, Edwards MH, Dennison EM, Cooper C. Epidemiology and
burden of osteoarthritis. Br Med Bull. 2013;105:185-199.
30. Mei-Dan O, Carmont MR, Laver L, et al. Platelet-rich plasma or hya-
luronate in the management of osteochondral lesions of the talus. Am
J Sports Med. 2012;40(3):534-541.
31. Niemeyer P, Laute V, Zinser W, et al. A prospective, randomized,
open-label, multicenter, phase III noninferiority trial to compare the
clinical efficacy of matrix-associated autologous chondrocyte
implantation with spheroid technology versus arthroscopic micro-
fracture for cartilage defects of the knee. Orthop J Sports Med.
2019;7(7):2325967119854442.
32. Ogura T, Merkely G, Bryant T, Winalski CS, Minas T. Autologous
chondrocyte implantation ‘‘segmental-sandwich’’ technique for
deep osteochondral defects in the knee: clinical outcomes and cor-
relation with magnetic resonance imaging findings. Orthop J Sports
Med. 2019;7(5):2325967119847173.
33. Park KH, Hwang Y, Han SH, et al. Primary versus secondary osteo-
chondral autograft transplantation for the treatment of large osteo-
chondral lesions of the talus. Am J Sports Med. 2018;46(6):1389-
1396.
34. Quirbach S, Trattnig S, Marlovits S, et al. Initial results of in vivo high-
resolution morphological and biochemical cartilage imaging of
patients after matrix-associated autologous chondrocyte transplan-
tation (MACT) of the ankle. Skeletal Radiol. 2009;38(8):751-760.
35. Rolf CG, Barclay C, Riyami M, George J. The importance of early
arthroscopy in athletes with painful cartilage lesions of the ankle: a pro-
spective study of 61 consecutive cases. J Orthop Surg Res. 2006;1:4.
36. Schneider W, Jurenitsch S. Normative data for the American Ortho-
pedic Foot and Ankle Society ankle-hindfoot, midfoot, hallux and
lesser toes clinical rating system. Int Orthop. 2016;40(2):301-306.
37. Sherman SL, Thyssen E, Nuelle CW. Osteochondral autologous
transplantation. Clin Sports Med. 2017;36(3):489-500.
38. Shimozono Y, Hurley ET, Nguyen JT, Deyer TW, Kennedy JG. Allo-
graft compared with autograft in osteochondral transplantation for
the treatment of osteochondral lesions of the talus. J Bone Joint
Surg Am. 2018;100(21):1838-1844.
39. SooHoo NF, Shuler M, Fleming LL; American Orthopaedic Foot and
Ankle Society. Evaluation of the validity of the AOFAS clinical rating
systems by correlation to the SF-36. Foot Ankle Int. 2003;24(1):50-55.
40. Stuber J, Zech S, Bay R, Qazzaz A, Richter M. Normative data of the
Visual Analogue Scale Foot and Ankle (VAS FA) for pathological con-
ditions. Foot Ankle Surg. 2011;17(3):166-172.
41. Van Lieshout EM, De Boer AS, Meuffels DE, et al. American Ortho-
paedic Foot and Ankle Society (AOFAS) Ankle-Hindfoot Score:
a study protocol for the translation and validation of the Dutch lan-
guage version. BMJ Open. 2017;7(2):e012884.
42. Walther M, Valderrabano V, Wiewiorski M, et al. Is there clinical evi-
dence to support autologous matrix-induced chondrogenesis (AMIC)
for chondral defects in the talus? A systematic review and meta-
analysis. Foot Ankle Surg. 2021;27(3):236-245.
43. Williams SK, Amiel D, Ball ST, et al. Prolonged storage effects on the
articular cartilage of fresh human osteochondral allografts. J Bone
Joint Surg Am. 2003;85(11):2111-2120.
44. Yoon HS, Park YJ, Lee M, Choi WJ, Lee JW. Osteochondral autolo-
gous transplantation is superior to repeat arthroscopy for the treat-
ment of osteochondral lesions of the talus after failed primary
arthroscopic treatment. Am J Sports Med. 2014;42(8):1896-1903.
For reprints and permission queries, please visit SAGE’s Web site at http://www.sagepub.com/journals-permissions
AJSM Vol. XX, No. X, XXXX Surgical Management of Talar Chondral Defects 7
